'Biomarker' presentation slideshows

An Introduction to Biomarkers for Statisticians: A Brief Guide to Utilizing

An Introduction to Biomarkers for Statisticians: A Brief Guide to Utilizing the Most Appropriate Analytical Tool. Ena Bromley and Lin Li. What are Biomarkers?.

636 views • 63 slides

Analysis of Biomolecular Interactions

Analysis of Biomolecular Interactions. Tasks in the Post-Genomic Era To understand the functions, modifications, and regulations of every encoded proteins in cells. Analysis of protein interactions in parallel with high speed. Interactions between Proteins and Small Molecules.

585 views • 41 slides

Biomarker Development and Validation Practices & Experiences

Biomarker Development and Validation Practices & Experiences. Shawn Li, M.D., Ph.D. October 1, 2012. Presentation outline. Introduction Frontage Capabilities and Approaches Case Studies Challenges and Solutions: Measurement of Analyte in Presence of Endogenous Protein Qualified Assays.

364 views • 25 slides

Nutrient and Physical Activity Biomarker Studies in the WHI

Nutrient and Physical Activity Biomarker Studies in the WHI.

225 views • 14 slides

Tmm: Analysis of Multiple Microarray Data Sets

297 views • 14 slides

Tmm: Analysis of Multiple Microarray Data Sets

147 views • 14 slides

DESIGN OF A DISEASE SPECIFIC MASTER PROTOCOL

DESIGN OF A DISEASE SPECIFIC MASTER PROTOCOL. Jeff Allen, PhD Executive Director Friends of Cancer Research. Current Challenges. Each potential new therapy is typically tested independently from other therapies seeking to treat the same condition

677 views • 12 slides

Validity and Reproducibility of Exposure Measurements: The Method of Triads

Validity and Reproducibility of Exposure Measurements: The Method of Triads. Edmond K. Kabagambe and Hannia Campos Harvard School of Public Health. Suggested reading. Kaaks, RJ. (1997). Am J Clin Nutr 65:1232S-1239S Ocke and Kaaks (1997). Am J Clin Nutr 65:1240S-1245S

334 views • 12 slides

The Future of Clinical Trials: New Model to Enhance Efficiency

The Future of Clinical Trials: New Model to Enhance Efficiency. Jeff Allen, PhD Executive Director Friends of Cancer Research. Current Challenges. Each potential new therapy is typically tested independently from other therapies seeking to treat the same condition

172 views • 12 slides

The Future of Clinical Trials: New Model to Enhance Efficiency

The Future of Clinical Trials: New Model to Enhance Efficiency. Jeff Allen, PhD Executive Director Friends of Cancer Research. Current Challenges. Each potential new therapy is typically tested independently from other therapies seeking to treat the same condition

126 views • 12 slides

Biomarkers HCLS F2F 2009-11-03

122 views • 5 slides

Biomarkers HCLS F2F 2009-11-03

59 views • 5 slides

Biomarker H-score

0.3 p =0.002. 0.06 p =0.506. 0.34 p <0.001. 0.42 p <0.001. 0.38 p <0.001. 0.33 p <0.001. 0.24 p =0.019. 0.12 p =0.218. Biomarker H-score. Biomarker H-score.

122 views • 1 slides

Peptide Biomarkers

Due to their multiple involvement in biological systems, peptides are ideal biomarker candidates. According to the NIH definition, "biomarker" has been defined as a characteristic that can be measured and evaluated as an indicator of normal biologic processes, pathologic processes or pharmacologic responses to therapeutic intervention. Since peptides can migrate between compartments of an organism, lots of pathogenic processes can be reflected by characteristic, pathognomonic changes of the composition of peptides in different body fluids. Peptide abundance changes associated with various diseases have already been detected.

16 views • 1 slides